^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Evaluation of patients with surgically resected high-risk melanoma receiving adjuvant therapy in routine clinical practice in the United States.
Published date:
05/19/2021
Excerpt:
CONTRADICTING EVIDENCE: Patients diagnosed with stage III advanced melanoma...received approved first-line (1L) adjuvant therapy after January 2018 with checkpoint inhibitors (CPIs; eg, nivolumab, pembrolizumab) or targeted therapies (TTs; eg, dabrafenib/trametinib), had 6 months’ follow-up...In Cohort 3, for patients with documented BRAF mutations, 6- and 12-month OS rates from disease recurrence were 79.1% and 49.4%, respectively, which were greater than for those with BRAF-WT tumors (54.1% and 46.3%).
DOI:
10.1200/JCO.2021.39.15_suppl.9577
Source:
Title:
Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment
Published date:
12/15/2020
Excerpt:
Next-generation sequencing (NGS) was performed using tumor specimens collected from 178 Asian patients with metastatic melanoma receiving CPIs….Univariate analysis identified TP53 and BRAF mutations, NF2 deletions, and BIRC2 amplifications as poor prognostic factors for PFS (P < 0.05).
DOI:
10.1016/j.esmoop.2020.100002
Source:
Title:
Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma.
Published date:
05/13/2020
Excerpt:
We reviewed clinical and neuroimaging data of 62 melanoma patients, including 26 patients with BRAF-mutant tumors, with newly diagnosed brain metastases treated with immune checkpoint inhibitors (ICI) alone (n = 10, group 1), SRT alone or in combination with other systemic therapies (n = 20, group 2) or ICI plus SRT (n = 32, group 3)....Pseudoprogression rates were similar after SRT alone or in combination with ICI.
DOI:
10.1200/JCO.2020.38.15_suppl.2532
Source:
Title:
Association of increased somatic mutations in metastatic melanoma patients with clinical outcome.
Published date:
05/16/2018
Excerpt:
...108 metastatic melanoma patients enrolled...All patients received immunotherapy first line treatment...Worse PFS was observed with EGFR (HR = 8.22, p = 0.04), PTEN (HR = 1.92, p = 0.04) and non-canonical BRAF (HR = 1.77, p = 0.04) mutations....those that harbored a higher number of mutations were associated with a worse PFS...
DOI:
10.1200/JCO.2018.36.15_suppl.e21568
